This webinar focuses on important factors related to use of LAIs for substance use disorders, such as target patient populations, indications, product preparation, dosing, administration techniques, adverse effects, storage requirements, and monitoring recommendations.
Target Audience
We invite you to participate in this online course if you are a pharmacist, nurse, or other health care professional interested in administering and/or learning more about psychotropic long-acting injectables for patients living with serious mental illness or substance use disorders.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Complete the pre-test (if applicable) before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete the evaluation at the end of the activity.
- If necessary, complete the post-test retest no later than the closing activity date.
- Receive a passing grade (70%).
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Benjamin Miskle, MBA, PharmD
Clinical Assistant Professor/Clinical Pharmacy Specialist
University of Iowa
Iowa City, IA
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Vivitrol® for stimulant use disorder.
This presentation includes the use of brand name medications due to similarities with generic names of LAI products.
All relevant relationships have been mitigated.
Learning Objectives
- Describe dosing and administration, including product preparation, for naltrexone long acting injectable (LAI) and buprenorphine LAI.
- Identify contraindications, warnings/precautions, common adverse effects and potential mitigation strategies for naltrexone LAI and buprenorphine LAI.
- Describe the storage requirements and stability data of naltrexone LAI and buprenorphine LAI.
- Outline a plan for monitoring and follow up of a patient receiving naltrexone LAI or buprenorphine LAI.
Continuing Education Credit and Disclosures
Activity Dates: 05/31/2023 - 05/15/2026
ACPE Contact Hours: 0.75
ACPE Number: 0284-0000-23-025-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
Beth DeJongh, PharmD, BCPS, BCPP Director of Continuing Professional Development American Association of Psychiatric Pharmacists Lincoln, NE No Relevant Financial Relationships to Disclose |
Megan J. Ehret, PharmD, BCPP, MS BCPP Program Director Professor University of Maryland Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Vivitrol? for stimulant use disorder.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.